                         SEQUENCE LISTING

<110>  Toscana Biomarkers srl
       PRATESI, Federico
       ALCARO, Maria Claudia
       CHELLI, Mario
       LOLLI, Francesco
       PAOLINI, Ilaria
       PAPINI, Anna Maria
       ROVERO, Paolo
       MIGLIORINI, Paola
 
<120>  METHOD FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS

<130>  PCT 116128

<150>  EP 11167420.6
<151>  2011-05-25

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  50
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (23)..(23)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (35)..(35)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (36)..(36)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (40)..(40)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (45)..(45)
<223>  arginine or citrulline residue

<400>  1

Ser Gly Xaa Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly Gly Ala Lys 
1               5                   10                  15      


Xaa His Xaa Lys Val Leu Xaa Asp Asn Ile Gln Gly Ile Thr Lys Pro 
            20                  25                  30          


Ala Ile Xaa Xaa Leu Ala Xaa Xaa Gly Gly Val Lys Xaa Ile Ser Gly 
        35                  40                  45              


Leu Ile 
    50  


<210>  2
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  arginine or citrulline residue

<400>  2

Gly Gln Ser Xaa Gly Gln Ser Xaa Gly Xaa Gly Xaa Gly Xaa Gly Xaa 
1               5                   10                  15      


Gly Xaa Gly Lys Gly 
            20      


<210>  3
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  arginine or citrulline residue

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  arginine or citrulline residue

<400>  3

Gly Gly Asp Asn His Gly Xaa Gly Xaa Gly Xaa Gly Xaa Gly Xaa Gly 
1               5                   10                  15      


Gly Gly Xaa Pro Gly Ala Pro Gly 
            20                  


<210>  4
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  4

Gly Gln Ser Arg Gly Gln Ser Arg Gly Arg Gly Arg Gly Arg Gly Arg 
1               5                   10                  15      


Gly Arg Gly Lys Gly 
            20      


